<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289428</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP2001</org_study_id>
    <nct_id>NCT04289428</nct_id>
  </id_info>
  <brief_title>Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays</brief_title>
  <official_title>Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of novel point of care Hepatitis B diagnostic assays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the sensitivity of the following novel assays for evaluation of
      HBV infection and assessment of treatment eligibility;

        -  GeneXpert HBV DNA via Fingerstick testing,

        -  Dried Blood Spot based HBV DNA

        -  Point of care ALT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of the Xpert® HBV DNA fingerstick point of care assay</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the sensitivity and specificity of the Xpert® HBV DNA point of care assay from finger-stick whole blood samples compared to plasma samples collected via venipuncture and tested on the Roche COBAS AmpliPrep/COBAS TaqMan HBV (CAP/CTM HBV) V2 assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of the point of care ALT</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the sensitivity and specificity of the point of care ALT assay from finger-stick whole blood samples compared to standard of care ALT collected via venepuncture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of the Xpert® HBV DNA point of care assay on dried blood spots</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the sensitivity and specificity of the Xpert® HBV DNA point of care assay from dried blood spot samples compared to plasma samples collected via venipuncture and tested on the Roche COBAS AmpliPrep/COBAS TaqMan HBV (CAP/CTM HBV) V2 assay.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Not currently on antiviral therapy for HBV and HBV DNA detectable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Stable on HBV antiviral therapy for at least 3 months with HBV DNA &lt; 20 IU/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Xpert® HBV DNA fingerstick point of care assay</intervention_name>
    <description>Xpert® HBV DNA point of care assay from finger-stick whole blood</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Point of Care ALT</intervention_name>
    <description>Point of Care ALT from finger-stick whole blood</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Xpert® HBV DNA point of care assay from dried blood spot</intervention_name>
    <description>Xpert® HBV DNA point of care assay from dried blood spot</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried blood spot samples of capillary blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be enrolled into the study in two parts until the following sample sizes
        are met for the prospective samples Part A: At least 30 paired specimens of venous EDTA
        whole blood and DBS in treatment naive adults (HBV DNA detectable) Part B: At least 30
        paired specimens of venous EDTA whole blood and DBS in HBV DNA undetectable adults on
        antiviral therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have voluntarily signed the informed consent form.

          2. 18 years of age or older.

          3. HBsAg positive

          4. Part A: Not currently on antiviral therapy for HBV and HBV DNA detectable OR Part B:
             Stable on HBV antiviral therapy for at least 3 months with HBV DNA &lt; 20 IU/ml

        Exclusion Criteria:

        1) Inability or unwillingness to provide informed consent or abide by the requirements of
        the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Matthews, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Byrne</last_name>
    <phone>+61293850900</phone>
    <email>mbyrne@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Gail Matthews</last_name>
      <phone>+61293850900</phone>
      <email>gmatthews@kirby.unsw.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Diagnostics</keyword>
  <keyword>HBV DNA</keyword>
  <keyword>ALT</keyword>
  <keyword>Point of care</keyword>
  <keyword>Dried blood spot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

